COMMUNIQUÉS West-GlobeNewswire

Aino Health AB (publ): Aino Health signs cooperation agreement with Monetra Oulu Oy
30/09/2019
Aino Health and Monetra Oulu Oy have signed a cooperation agreement in Finland where Monetra Oulu Oy will sell all of Aino’s services and connected implementation services. This cooperation supports Aino’s expansion [...]
Dova Pharmaceuticals to be Acquired by Swedish Orphan Biovitrum AB (Sobi)
30/09/2019
Consideration of up to $29.00 per share includes $27.50 per share in upfront cash and an additional $1.50 per share upon regulatory approval of DOPTELET ® for chemotherapy-induced thrombocytopenia (CIT) as a Contingent [...]
OSE Immunotherapeutics Presents New Preclinical Data on its Novel Bispecific Checkpoint Inhibitor (BiCKI®) Platform Targeting PD-1 and Cytokines to Overcome Tumor Resistance to Checkpoint Inhibitor Blockade
30/09/2019
New data presented at the International Cancer Immunotherapy Conference (CICON) NANTES, France, Sept. 30, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Euronext: OSE) presented new data on its [...]
SPINEWAY : Spineway réalise une augmentation de capital de 1,3 M€
30/09/2019
Spineway réalise une augmentation de capital de 1,3 M€ SPINEWAY annonce la réalisation d’une augmentation de capital avec suppression du droit préférentiel de souscription au profit de la société d’investissements [...]
Change in number of shares and votes in Saniona AB (publ)
30/09/2019
PRESS RELEASE September 30, 2019 During September, the registered number of shares and votes in Saniona AB (publ) (“Saniona”) has increased due to conversion of convertible notes issued pursuant to the convertible notes [...]
Valneva Completes Recruitment for Phase 2 Studies of its Lyme Disease Vaccine Candidate VLA15
30/09/2019
Valneva Completes Recruitment for Phase 2 Studies of its Lyme Disease Vaccine Candidate VLA15 Saint-Herblain (France), September 30, 2019 – Valneva SE (“Valneva” or “the Company”), a biotech company developing and [...]
Valneva: Recrutement terminé pour les études de Phase 2 du candidat vaccin contre la maladie de Lyme VLA15
30/09/2019
Valneva: Recrutement terminé pour les études de Phase 2 du candidat vaccin contre la maladie de Lyme VLA15 Saint-Herblain (France), 30 septembre 2019 –Valneva SE (“Valneva” ou “le Groupe”), société de biotechnologie [...]
Novartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthma
30/09/2019
Once-daily QMF149 demonstrated superior improvement in lung function versus mometasone furoate, meeting primary endpoint[1] PALLADIUM is part of Phase III PLATINUM clinical development program, which evaluates inhaled [...]
Basilea reports at ESMO meeting that drug candidate derazantinib showed clinical benefit in intrahepatic cholangiocarcinoma (iCCA) patients with various FGFR2 genetic aberrations
30/09/2019
Basel, Switzerland, September 30, 2019 – Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that a post-hoc analysis of efficacy data from a previously completed phase 1/2 study with its oncology drug candidate [...]
Novartis announces positive results from Phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthma
30/09/2019
Once-daily QVM149 demonstrated statistically significant improvement in lung function versus QMF149, meeting primary endpoint[1],[2] IRIDIUM is largest study in Phase III PLATINUM clinical development program, which [...]
FDA approves Roche’s Rituxan (rituximab) in children with two rare blood vessel disorders
30/09/2019
Rituxan is the first and only FDA-approved treatment for paediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitis These two forms of vasculitis in children [...]
GARDP and Entasis Therapeutics Initiate Global Phase 3 Trial of Zoliflodacin, a First-in-Class Oral Antibiotic for the Treatment of Gonorrhea
30/09/2019
Randomized, open label trial will assess the efficacy and safety of zoliflodacin versus a combination of azithromycin and ceftriaxone, the current standard of care 87 million new gonorrhea infections estimated each year [...]
Addex Reports 2019 Half-Year Financial Results and Provides Corporate Update
30/09/2019
Geneva, Switzerland, September 30, 2019 – Addex Therapeutics (SIX: ADXN), a leading allosteric modulation-based drug discovery and development company, today reported its half-year financial results for the period ended [...]
Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.
30/09/2019
Basel, 30 September 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to [...]
Chi-Med to Discuss Surufatinib Phase III and U.S. Phase I/Ib Efficacy and Safety Data Presented at the 2019 ESMO Annual Meeting
29/09/2019
– Surufatinib achieved primary endpoint, reducing the risk of progression or death by 67% in patients with non-pancreatic neuroendocrine tumors (“NET”) in the Phase III SANET-ep study – – Preparations underway for the [...]
New Data Presented at ESMO Congress 2019 from the Arginase Inhibitor INCB001158 Alone and in Combination with Pembrolizumab
29/09/2019
Responses observed in patients with microsatellite stable (MSS) colorectal cancer, a disease not historically sensitive to checkpoint inhibition SOUTH SAN FRANCISCO, Calif., Sept. 29, 2019 (GLOBE NEWSWIRE) -- Calithera [...]
Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients
29/09/2019
In MONALEESA-3, Kisqali plus fulvestrant achieved statistically significant overall survival benefit vs. fulvestrant alone in postmenopausal women (HR=0.724; p=0.00455)[1] Kisqali is the only CDK4/6 inhibitor to [...]
Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients
29/09/2019
In MONALEESA-3, Kisqali plus fulvestrant achieved statistically significant overall survival benefit vs. fulvestrant alone in postmenopausal women (HR=0.724; p=0.00455)[1] Kisqali is the only CDK4/6 inhibitor to [...]
G1 Therapeutics Presents First Clinical Data on Oral SERD G1T48 Demonstrating Safety and Tolerability in Patients with Advanced Breast Cancer at ESMO 2019
29/09/2019
-- Company to host investor and analyst event, webcast and conference call today at 12:45 p.m. ET -- RESEARCH TRIANGLE PARK, N.C. and BARCELONA, SPAIN, Sept. 29, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: [...]

Pages